Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada

Ascendis Pharma (ASND) and Pendopharm have signed a distribution agreement under which the latter will oversee regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment Trans

MT NewswiresJul 5 21:58

Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday

With U.S. stock futures trading higher on Friday morning, some of the stocks that may grab investor focus today are as follows:Arkhouse Management and Brigade Capital Management increased their offer

BenzingaJul 5 16:24

Reported Thursday, Pendopharm Partners With Ascendis Pharma For Exclusive Distribution of TransCon PTH In Canada

Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransConTM PTH (palopegteriparatide) in Canada. Fina

BenzingaJul 5 14:05

Pendopharm Signs Exclusive Distribution Agreement With Ascendis Pharma A/S for TransCon PTH in Canada

Yahoo FinanceJul 5 00:48

European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading

European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.6% to 1,436.74 on the S&P Europe Select ADR Index. From continental Europe, the

MT NewswiresJul 3 23:25

Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 15.29% on an annualized basis producing an average annual return of 28.27%. Currently, Ascendis Pharma has a market

BenzingaJul 3 22:30